论文部分内容阅读
目的探讨自噬重要调控因子Beclin-1在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其临床意义。方法收集150例非小细胞肺癌患者的癌组织及癌旁组织并制成组织芯片,应用免疫组化的方法检测Beclin-1在肺癌组织及癌旁组织中的表达情况。分析Beclin-1的表达与肺癌不同临床参数之间的关系并对病例进行生存分析。结果 Beclin-1在肺癌组织的阳性表达率(26.00%)显著低于癌旁组织(82.00%)(P<0.05);肺鳞癌组织中Beclin-1的阳性表达率(34.66%)显著高于肺腺癌(17.34%)(P<0.05);Beclin-1的表达率在不同性别、年龄、分化程度、淋巴结转移、远处转移组间无显著差异(P>0.05);Beclin-1阴性表达的非小细胞肺癌患者的生存率显著低于阳性表达的患者(P<0.05)。结论 Beclin-1可能是一个非小细胞肺癌治疗的新的靶点,有可能成为非小细胞肺癌病理类型判断的辅助指标和预后评估候选指标之一。
Objective To investigate the expression of Beclin-1, an important autophagy regulatory factor in non-small cell lung cancer (NSCLC) and its clinical significance. Methods 150 cases of non-small cell lung cancer tissues and adjacent tissues were collected and made into tissue microarrays. The expression of Beclin-1 in lung cancer tissues and adjacent tissues was detected by immunohistochemistry. The relationship between the expression of Beclin-1 and different clinical parameters of lung cancer was analyzed and the survival analysis was performed. Results The positive rate of Beclin-1 in lung cancer (26.00%) was significantly lower than that in paracancerous tissues (82.00%) (P <0.05). The positive rate of Beclin-1 in lung squamous cell carcinoma was significantly higher than that of Beclin-1 (17.34%) (P <0.05). There was no significant difference in the expression of Beclin-1 between different gender, age, differentiation, lymph node metastasis and distant metastasis (P> 0.05) Of patients with non-small cell lung cancer had significantly lower survival rates than those with positive expression (P <0.05). Conclusion Beclin-1 may be a new target for the treatment of non-small cell lung cancer, which may be one of the adjunct and prognostic evaluation indicators for judging the pathological type of non-small cell lung cancer.